2 news items
Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors
MLYS
14 Jun 24
-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven
Goldman Sachs Initiates Coverage On Mineralys Therapeutics with Buy Rating, Announces Price Target of $30
MLYS
2 Apr 24
Goldman Sachs analyst Richard Law initiates coverage on Mineralys Therapeutics (NASDAQ:MLYS) with a Buy rating and announces Price Target of $30.
- Prev
- 1
- Next